Refine by
Ophthalmology Articles & Analysis
166 news found
Introduction Recent marketing efforts by loupe manufacturers have claimed to offer the “only clinically proven ergonomic loupe”. This assertion focuses on the benefits of refractive loupes with deflection prism, positioning them as the exclusive solution for chronic neck and back pain in dental professionals.5 However, while refractive loupes can improve posture by using refractive ...
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease. Glaucoma is a group of eye conditions that damage the optic nerve, often ...
Animal Hydrocolloids Animal-derived hydrocolloids are known for their strong protective colloid properties, good biocompatibility, stable batch, good mechanical strength, and that’s why they are extensively used as substrates or additives in many fields, including food, photography, cosmetics, artificial skin, wound dressings, ophthalmology, wastewater treatment, ...
Ace Therapeutics is a preclinical contract research provider engaged in ophthalmic diseases. To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of ...
Summary Attending a loupe fair is an exciting and essential milestone for dental and hygiene students. Loupes are a critical tool in modern dentistry, enhancing precision and ergonomics during procedures. Choosing the right pair of loupe and LED headlight can significantly impact your comfort and performance. Here’s a guide to help dental and hygiene students prepare for a loupe fair, ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. Following with the announcement of developing small molecule drug for glaucoma, Ace Therapeutics recently unveiled disease model customization services to accelerate ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, Ace Therapeutics announces its new vaccine development services to ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...
ByBayer AG
Thus, we welcome new research in extended treatment intervals that alleviate the situation for patients and the health care systems while achieving best visual acuity outcomes”, said Dr. Varun Chaudhary, Chief of Ophthalmology and Professor of Surgery at Hamilton Regional Eye Institute, McMaster University, Canada. ...
ByBayer AG
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg In total, 18 presentations on aflibercept 8 mg and Eylea (aflibercept 2 mg) reinforce Bayer’s commitment to advancing treatment of patients with exudative retinal ...
ByBayer AG
Applications of the CO2 laser Because of its early introduction, the CO2 laser is now used in more than just medical aesthetics, for example, in surgery and ophthalmology as a routine treatment, but we will only describe its use in the field of skin aesthetics. ...
Today the CO2 laser beauty machine is not only limited to skin aesthetics, but can also be used for routine treatments in gynaecology, surgery and ophthalmology. Bvlaser is a CO2 laser beauty machine factory manufacturer, we have portable CO2 fractional laser machine for sale. ...
Her leadership and extensive drug development experience at Amgen, Merck, and Greenfire Bio aligns with the company’s drug discovery interests across multiple therapeutic areas, including cardio-metabolic, pulmonary, inflammatory ophthalmology, renal and fibrotic diseases. Mo Tabrizi, PhD, Vice President of Preclinical and Nonclinical Development, brings over 25 years of ...
Viral vectors can be used for the treatment of various diseases such as: muscular, metabolic, hematologic, ophthalmologic, and infectious diseases as well as different types of cancer. ...
ByNuvonis
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of preclinical data on its program VG801 in ...
With these top-tier investors and a strong ophthalmologic network supporting us, we are now in an excellent position to accelerate our development ...
Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. Amar Sawhney and his teams, it seems, can make medical hydrogels do ...
BRIM plans to harness its proprietary PDSP platform to address other diseases beyond ophthalmology and bring sustainable and affordable healthcare innovation to the ...
Andreas Stahl, Head of the University Department of Ophthalmology, University Medical Center, Greifswald, Germany. Bayer will apply for a patent term extension for the European patent covering aflibercept, the active ingredient in Eylea, of six months once the European Commission adopts a decision for a label extension of Eylea. ...
ByBayer AG
“These data show unprecedented durability of aflibercept 8 mg in patients living with age-related macular degeneration and diabetic macular edema, who also experienced significant anatomical improvements at week 48,” said Jean-François Korobelnik, Professor of Ophthalmology and Head of the Department of Ophthalmology at University Hospital of ...
ByBayer AG